Compounds > oxonic acid
Page last updated: 2024-11-02

oxonic acid and Biliary Tract Cancer

oxonic acid has been researched along with Biliary Tract Cancer in 59 studies

Oxonic Acid: Antagonist of urate oxidase.

Research Excerpts

ExcerptRelevanceReference
"Gemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration."9.30Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. ( Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S, 2019)
"To evaluate each arm independently and compare adjuvant gemcitabine (GEM) and S-1 chemotherapy after major hepatectomy (hemihepatectomy or trisectionectomy) for biliary tract cancer (BTC)."9.30A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. ( Ajiki, T; Gotoh, K; Hatano, E; Hirose, T; Ikai, I; Ioka, T; Kamei, K; Kobayashi, S; Morita, S; Nagano, H; Sakai, D; Satake, H; Seo, S; Terajima, H; Tohyama, T; Tomokuni, A; Uchida, Y, 2019)
"Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)."9.24A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017)
"This study aimed to determine the maximum tolerated dose and the recommended dose of combining S-1 with gemcitabine and cisplatin for advanced biliary tract adenocarcinoma first-line therapy."9.22Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. ( Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H, 2016)
"A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC)."9.20Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. ( Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY, 2015)
"S-1 and gemcitabine (GS) combination therapy is a promising treatment for advanced biliary tract cancer (BTC)."9.20Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer. ( Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M, 2015)
"To evaluate the dose-limiting toxicities (DLTs) and determine the maximum-tolerated dose (MTD) and recommended dose (RD) of combination chemotherapy with gemcitabine, cisplatin and S-1 which is an oral fluoropyrimidine pro-drug in patients with advanced biliary tract cancer."9.20Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer. ( Imaizumi, H; Iwai, T; Kaneko, T; Kida, M; Koizumi, W; Miyazawa, S; Okuwaki, K; Takezawa, M; Watanabe, A; Yamauchi, H, 2015)
"Gemcitabine/cisplatin combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC)."9.20A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). ( Ajiki, T; Fujiwara, Y; Hatano, E; Ikoma, H; Ikuta, S; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Kubo, S; Marubashi, S; Miyamoto, A; Morita, S; Nagano, H; Sakai, D; Seo, S; Shiomi, H; Terajima, H; Yanagimoto, H, 2015)
"To develop a triplet regimen containing gemcitabine, cisplatin, and S-1 (GPS), we assessed the recommended dose for patients with untreated advanced biliary tract cancer in this phase I study."9.20Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer. ( Araki, M; Endo, S; Hamano, Y; Hasegawa, N; Hyodo, I; Imanishi, M; Ishida, H; Ito, Y; Kobayashi, M; Moriwaki, T; Sato, D; Shimoyamada, M; Sugaya, A; Yoshida, S, 2015)
"To date, gemcitabine-based or fluoropyrimidine-based regimens are recommended for unresectable advanced biliary tract cancer."9.20Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. ( Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K, 2015)
"In order to confirm the impact of adding S-1 to gemcitabine, we conducted a randomized phase II study to compare the combination therapy of gemcitabine plus S-1 to gemcitabine monotherapy in patients with advanced biliary tract cancer."9.17A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. ( Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Kogure, H; Koike, K; Maetani, I; Maguchi, H; Mukai, T; Nakai, Y; Okabe, Y; Sasahira, N; Sasaki, T; Toda, N; Yasuda, I, 2013)
"Gemcitabine (GEM)-based chemotherapy has been used worldwide as the first-line treatment for advanced biliary tract cancer (BTC)."9.17A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. ( Boku, N; Furuse, J; Ikeda, M; Nagakawa, T; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Suzuki, E; Yanagimoto, H, 2013)
"The oral fluoropyrimidine, S-1, combined with or without gemcitabine is considered to be a promising agent for treating advanced biliary tract cancer; gemcitabine plus cisplatin is the current standard regimen."9.17Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). ( Boku, N; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Mizusawa, J; Morizane, C; Okusaka, T; Takashima, A; Ueno, M, 2013)
"We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA)."9.16Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. ( Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2012)
"We aimed to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the addition of S-1, an oral fluorouracil derivative, to gemcitabine and cisplatin combination therapy, which is the current standard treatment for advanced biliary tract cancer."9.16Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). ( Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D, 2012)
"Gemcitabine is widely used for the treatment of advanced biliary tract cancer (BTC) as first-line chemotherapy."9.16Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. ( Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y, 2012)
"Gemcitabine/S-1 combination chemotherapy offered a promising survival benefit with acceptable toxicity in patients with advanced biliary tract cancer."9.15A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. ( Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K, 2011)
"A randomized Phase II selection design trial comparing gemcitabine plus S-1 combination therapy with S-1 monotherapy for chemo-naïve unresectable or recurrent biliary tract cancer patients was started in Japan."9.14Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805). ( Fukuda, H; Furuse, J; Ishii, H; Morizane, C; Nakamura, K; Okusaka, T; Takashima, A, 2010)
"To evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer."9.14Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. ( Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I, 2010)
"Prognostic factors for patients with relapse and unresectable biliary tract cancer, treated with Tegafur Gimeracil Oteracil Potassium (S-1) after failure of gemcitabine (GEM), are unclear."8.12[Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine]. ( Funahara, H; Hiraki, K; Kikkawa, A; Matsumoto, S; Nakai, M, 2022)
"Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC)."8.02Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. ( Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2021)
"No standard second-line chemotherapy has been yet established for gemcitabine-refractory biliary tract cancer (BTC)."7.88The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer. ( Furuse, J; Kasuga, A; Kawai, K; Kobayashi, T; Nagashima, F; Naruge, D; Okano, N; Yamauchi, Y, 2018)
"Objective This study aimed to compare the safety and efficacy of the combination therapy of gemcitabine and S-1 (GS) versus gemcitabine and cisplatin (GC) in patients with advanced biliary tract cancer (BTC)."7.85Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study. ( Akiyama, D; Isayama, H; Ishigaki, K; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Uchino, R; Yagioka, H, 2017)
"Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC)."7.78An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. ( Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H, 2012)
"Adjuvant gemcitabine plus S-1 chemotherapy may be one of several factors contributing to improved outcomes after aggressive surgical resection of advanced biliary carcinoma in recent years."7.75Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakamura, H; Nakashima, A; Sudo, T; Sueda, T; Uemura, K, 2009)
"Resminostat is an oral histone deacetylase inhibitor."7.01A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. ( Fukutomi, A; Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Kajiwara, T; Katanuma, A; Kobayashi, S; Komatsu, Y; Makino, K; Mizuno, N; Moriwaki, T; Morizane, C; Muto, M; Nakai, Y; Negoro, Y; Nemoto, N; Ozaka, M; Sakai, D; Shimizu, S; Tsuda, M; Tsuji, A; Ueno, M, 2021)
"To evaluate each arm independently and compare adjuvant gemcitabine (GEM) and S-1 chemotherapy after major hepatectomy (hemihepatectomy or trisectionectomy) for biliary tract cancer (BTC)."5.30A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. ( Ajiki, T; Gotoh, K; Hatano, E; Hirose, T; Ikai, I; Ioka, T; Kamei, K; Kobayashi, S; Morita, S; Nagano, H; Sakai, D; Satake, H; Seo, S; Terajima, H; Tohyama, T; Tomokuni, A; Uchida, Y, 2019)
"Gemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration."5.30Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. ( Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S, 2019)
"Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)."5.24A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017)
"This study aimed to determine the maximum tolerated dose and the recommended dose of combining S-1 with gemcitabine and cisplatin for advanced biliary tract adenocarcinoma first-line therapy."5.22Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. ( Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H, 2016)
"To develop a triplet regimen containing gemcitabine, cisplatin, and S-1 (GPS), we assessed the recommended dose for patients with untreated advanced biliary tract cancer in this phase I study."5.20Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer. ( Araki, M; Endo, S; Hamano, Y; Hasegawa, N; Hyodo, I; Imanishi, M; Ishida, H; Ito, Y; Kobayashi, M; Moriwaki, T; Sato, D; Shimoyamada, M; Sugaya, A; Yoshida, S, 2015)
"S-1 and gemcitabine (GS) combination therapy is a promising treatment for advanced biliary tract cancer (BTC)."5.20Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer. ( Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M, 2015)
"A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC)."5.20Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. ( Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY, 2015)
"To evaluate the dose-limiting toxicities (DLTs) and determine the maximum-tolerated dose (MTD) and recommended dose (RD) of combination chemotherapy with gemcitabine, cisplatin and S-1 which is an oral fluoropyrimidine pro-drug in patients with advanced biliary tract cancer."5.20Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer. ( Imaizumi, H; Iwai, T; Kaneko, T; Kida, M; Koizumi, W; Miyazawa, S; Okuwaki, K; Takezawa, M; Watanabe, A; Yamauchi, H, 2015)
"Gemcitabine/cisplatin combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC)."5.20A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). ( Ajiki, T; Fujiwara, Y; Hatano, E; Ikoma, H; Ikuta, S; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Kubo, S; Marubashi, S; Miyamoto, A; Morita, S; Nagano, H; Sakai, D; Seo, S; Shiomi, H; Terajima, H; Yanagimoto, H, 2015)
"To date, gemcitabine-based or fluoropyrimidine-based regimens are recommended for unresectable advanced biliary tract cancer."5.20Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. ( Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K, 2015)
"In order to confirm the impact of adding S-1 to gemcitabine, we conducted a randomized phase II study to compare the combination therapy of gemcitabine plus S-1 to gemcitabine monotherapy in patients with advanced biliary tract cancer."5.17A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. ( Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Kogure, H; Koike, K; Maetani, I; Maguchi, H; Mukai, T; Nakai, Y; Okabe, Y; Sasahira, N; Sasaki, T; Toda, N; Yasuda, I, 2013)
"Gemcitabine (GEM)-based chemotherapy has been used worldwide as the first-line treatment for advanced biliary tract cancer (BTC)."5.17A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. ( Boku, N; Furuse, J; Ikeda, M; Nagakawa, T; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Suzuki, E; Yanagimoto, H, 2013)
"The oral fluoropyrimidine, S-1, combined with or without gemcitabine is considered to be a promising agent for treating advanced biliary tract cancer; gemcitabine plus cisplatin is the current standard regimen."5.17Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). ( Boku, N; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Mizusawa, J; Morizane, C; Okusaka, T; Takashima, A; Ueno, M, 2013)
"We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA)."5.16Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. ( Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2012)
"We aimed to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the addition of S-1, an oral fluorouracil derivative, to gemcitabine and cisplatin combination therapy, which is the current standard treatment for advanced biliary tract cancer."5.16Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). ( Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D, 2012)
"Gemcitabine is widely used for the treatment of advanced biliary tract cancer (BTC) as first-line chemotherapy."5.16Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. ( Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y, 2012)
"Gemcitabine/S-1 combination chemotherapy offered a promising survival benefit with acceptable toxicity in patients with advanced biliary tract cancer."5.15A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. ( Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K, 2011)
"A randomized Phase II selection design trial comparing gemcitabine plus S-1 combination therapy with S-1 monotherapy for chemo-naïve unresectable or recurrent biliary tract cancer patients was started in Japan."5.14Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805). ( Fukuda, H; Furuse, J; Ishii, H; Morizane, C; Nakamura, K; Okusaka, T; Takashima, A, 2010)
"To evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer."5.14Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. ( Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I, 2010)
"Prognostic factors for patients with relapse and unresectable biliary tract cancer, treated with Tegafur Gimeracil Oteracil Potassium (S-1) after failure of gemcitabine (GEM), are unclear."4.12[Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine]. ( Funahara, H; Hiraki, K; Kikkawa, A; Matsumoto, S; Nakai, M, 2022)
"In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC)."4.12The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113. ( Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Iwai, T; Kamata, K; Kataoka, T; Kato, N; Kawamoto, Y; Kojima, Y; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nishina, T; Okamura, K; Okano, N; Okusaka, T; Oono, T; Sekimoto, M; Shimizu, K; Shimizu, S; Shioji, K; Shirakawa, H; Sudo, K; Tobimatsu, K; Todaka, A; Ueno, M; Yamada, I; Yamaguchi, H; Yamashita, T, 2022)
"Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC)."4.02Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. ( Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2021)
"No standard second-line chemotherapy has been yet established for gemcitabine-refractory biliary tract cancer (BTC)."3.88The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer. ( Furuse, J; Kasuga, A; Kawai, K; Kobayashi, T; Nagashima, F; Naruge, D; Okano, N; Yamauchi, Y, 2018)
"Objective This study aimed to compare the safety and efficacy of the combination therapy of gemcitabine and S-1 (GS) versus gemcitabine and cisplatin (GC) in patients with advanced biliary tract cancer (BTC)."3.85Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study. ( Akiyama, D; Isayama, H; Ishigaki, K; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Uchino, R; Yagioka, H, 2017)
"This study enrolled 100 patients with Union for International Cancer Control (UICC) stages I-IV biliary tract cancer who underwent surgical resection, including 16 who received sequential adjuvant chemotherapy with gemcitabine or S-1."3.79Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients. ( Harada, N; Ikeda, T; Ikegami, T; Kawanaka, H; Maehara, Y; Matsuura, H; Morita, M; Okadome, K; Oki, E; Saeki, H; Shirabe, K; Soejima, Y; Uchiyama, H; Yamashita, Y; Yoshizumi, T, 2013)
"Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC)."3.78An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. ( Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H, 2012)
"Gemcitabine has been widely used, and cisplatin plus gemcitabine is considered as standard first-line chemotherapy for patients with advanced biliary tract cancer."3.78A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer. ( Andou, T; Kameda, R; Kobayashi, S; Morinaga, S; Ohkawa, S; Ueno, M; Yamamoto, N, 2012)
"We analyzed 56 consecutive patients with advanced biliary tract cancer who had received gemcitabine and S-1 combination chemotherapy as first-line palliative chemotherapy."3.77Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. ( Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y, 2011)
"Adjuvant gemcitabine plus S-1 chemotherapy may be one of several factors contributing to improved outcomes after aggressive surgical resection of advanced biliary carcinoma in recent years."3.75Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakamura, H; Nakashima, A; Sudo, T; Sueda, T; Uemura, K, 2009)
"Resminostat is an oral histone deacetylase inhibitor."3.01A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. ( Fukutomi, A; Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Kajiwara, T; Katanuma, A; Kobayashi, S; Komatsu, Y; Makino, K; Mizuno, N; Moriwaki, T; Morizane, C; Muto, M; Nakai, Y; Negoro, Y; Nemoto, N; Ozaka, M; Sakai, D; Shimizu, S; Tsuda, M; Tsuji, A; Ueno, M, 2021)
"S-1 is widely used to treat biliary tract cancer and pancreatic cancer in Japan."2.90Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. ( Hara, R; Hashimoto, Y; Ikeda, M; Kobayashi, S; Kondo, S; Mitsunaga, S; Morizane, C; Nakamura, O; Ohno, I; Okusaka, T; Sakamoto, Y; Sasaki, M; Takahashi, H; Ueno, H, 2019)
" Pharmacokinetic analysis of S-1 was performed at cycle 1."2.76Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. ( Bae, KS; Chang, HM; Hong, YS; Jang, G; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, SS; Lim, HS; Ryu, MH; Shin, JG, 2011)
"Biliary tract cancers are among the most aggressive tumors with a poor prognosis."2.73Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer. ( Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Lee, GW; Oh, SY, 2008)
"Optimal chemotherapy for advanced biliary tract cancer (BTC) is yet to be defined."2.73A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. ( Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, HG; Kim, JH; Kim, SW; Kim, TY; Kim, YJ; Lee, KW; Lee, SH; Oh, DY; Oh, SY; Yoon, YB, 2008)
"In the field of adjuvant therapy for biliary tract cancer, the British BILCAP (capecitabine compared with observation in resected biliary tract cancer) study revealed longer median overall survival in the capecitabine group than in the observation group in the per-protocol analysis (but not in the intention-to-treat analysis), bringing a shift toward postoperative management."2.66Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. ( Ban, D; Esaki, M; Furuse, J; Ioka, T; Ishii, H; Nara, S; Okusaka, T; Shimada, K; Takamoto, T, 2020)
"Biliary tract cancers are a group of rare heterogeneous malignant tumours."2.58Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. ( Abdel-Rahman, O; Elhalawani, H; Elsayed, Z, 2018)

Research

Studies (59)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (18.64)29.6817
2010's40 (67.80)24.3611
2020's8 (13.56)2.80

Authors

AuthorsStudies
Yamada, I1
Morizane, C10
Okusaka, T15
Mizusawa, J5
Kataoka, T1
Ueno, M5
Ikeda, M12
Okano, N4
Todaka, A2
Shimizu, S3
Mizuno, N3
Sekimoto, M1
Tobimatsu, K2
Yamaguchi, H2
Nishina, T1
Shirakawa, H1
Kojima, Y2
Oono, T1
Kawamoto, Y2
Furukawa, M2
Iwai, T3
Sudo, K1
Okamura, K1
Yamashita, T2
Kato, N2
Shioji, K2
Shimizu, K3
Nakagohri, T2
Kamata, K2
Ishii, H9
Furuse, J14
Nakai, M1
Kikkawa, A1
Funahara, H1
Matsumoto, S2
Hiraki, K1
Katayama, H2
Ozaka, M2
Sugimori, K1
Fukutomi, A3
Hara, H1
Yanagimoto, H3
Wada, K1
Yane, K1
Nakamori, S2
Asagi, A1
Yukisawa, S1
Kawabe, K1
Sugimoto, R1
Nakamura, K2
Miyakawa, H1
Hosokawa, A1
Ioka, T5
Seita, K1
Ebata, T2
Mizuno, T2
Maeda, A1
Yamaguchi, R1
Kurumiya, Y1
Sakamoto, E1
Hiramatsu, K1
Ando, M1
Nagino, M1
Akhoundova Sanoyan, D1
McNamara, MG1
Lamarca, A1
Valle, JW1
Nara, S1
Esaki, M1
Ban, D1
Takamoto, T1
Shimada, K2
Sakai, D4
Komatsu, Y1
Nakai, Y8
Tsuda, M1
Muto, M1
Tsuji, A1
Katanuma, A1
Moriwaki, T2
Kajiwara, T1
Negoro, Y1
Nemoto, N1
Kobayashi, S6
Makino, K1
Inoue, H1
Yamazaki, K1
Fushiki, K1
Shirasu, H1
Kawakami, T1
Tsushima, T1
Hamauchi, S1
Yokota, T1
Machida, N1
Onozawa, Y1
Andoh, A1
Yasui, H1
Yoo, C1
Han, B2
Kim, HS3
Kim, KP3
Kim, D1
Jeong, JH1
Lee, JL5
Kim, TW5
Kim, JH5
Choi, DR2
Ha, HI2
Seo, J1
Chang, HM4
Ryoo, BY1
Zang, DY2
Nakachi, K2
Konishi, M2
Eba, J1
Fukuda, H3
Kasuga, A2
Kawai, K2
Yamauchi, Y1
Kobayashi, T2
Naruge, D2
Nagashima, F2
Abdel-Rahman, O1
Elsayed, Z1
Elhalawani, H1
Saiura, A1
Sugiyama, M2
Sakamoto, H1
Shimamura, T1
Ohta, T1
Ohno, I2
Ueno, H4
Mitsunaga, S2
Hashimoto, Y3
Kondo, S2
Sasaki, M2
Sakamoto, Y2
Takahashi, H2
Hara, R1
Nakamura, O1
Nagano, H3
Tomokuni, A1
Gotoh, K1
Hatano, E4
Seo, S2
Terajima, H2
Uchida, Y1
Ajiki, T3
Satake, H1
Kamei, K1
Tohyama, T1
Hirose, T1
Ikai, I2
Morita, S2
Suzuki, E1
Ohkawa, S4
Nagakawa, T1
Boku, N4
Sato, T3
Takashima, A2
Hamamoto, Y1
Harada, N1
Shirabe, K1
Yoshizumi, T1
Ikegami, T1
Uchiyama, H1
Soejima, Y1
Yamashita, Y1
Saeki, H1
Oki, E1
Kawanaka, H1
Morita, M1
Ikeda, T1
Matsuura, H1
Okadome, K1
Maehara, Y1
Kim, HM1
Lee, KJ1
Cha, J1
Chung, MJ1
Bang, S1
Seong, J1
Song, SY1
Park, SW1
Uwagawa, T2
Sakamoto, T2
Abe, K1
Okui, N1
Hata, D1
Shiba, H2
Futagawa, Y1
Aiba, K1
Yanaga, K2
Kanai, M3
Fujiwara, Y2
Marubashi, S1
Miyamoto, A1
Shiomi, H1
Kubo, S1
Ikuta, S1
Ikoma, H1
Kodama, Y2
Sasaki, T7
Isayama, H7
Ito, Y8
Yasuda, I3
Toda, N6
Yagioka, H5
Matsubara, S5
Hanada, K2
Maguchi, H2
Kamada, H2
Hasebe, O3
Mukai, T2
Okabe, Y3
Maetani, I3
Koike, K5
Kim, HY1
Oh, HS1
Jeon, JY1
Cho, JW1
Park, CK1
Kim, MJ2
Song, H1
Kwon, JH1
Jung, JY1
Ishiwatari, H1
Hayashi, T1
Yoshida, M1
Ono, M1
Miyanishi, K1
Sato, Y1
Takimoto, R1
Kobune, M1
Kato, J1
Ishida, H1
Araki, M1
Endo, S1
Yoshida, S1
Kobayashi, M1
Hamano, Y1
Sugaya, A1
Shimoyamada, M1
Hasegawa, N1
Imanishi, M1
Sato, D1
Hyodo, I1
Watanabe, A1
Kida, M1
Miyazawa, S1
Okuwaki, K1
Kaneko, T1
Yamauchi, H1
Takezawa, M1
Imaizumi, H1
Koizumi, W1
Furukawa, K1
Tsutsumi, J1
Shoji, H1
Lee, DW1
Im, SA3
Kim, YJ2
Yang, Y1
Rhee, J1
Na, II1
Lee, KH1
Kim, TY4
Han, SW1
Choi, IS2
Oh, DY3
Bang, YJ3
Takahara, N1
Ishigaki, K1
Saito, K1
Akiyama, D1
Uchino, R1
Mizuno, S3
Kogure, H6
Togawa, O5
Tada, M5
Arima, S1
Okamoto, T1
Toki, M1
Suzuki, Y1
Kitamura, H1
Takasu, A1
Oh, SY2
Lee, GW1
Kim, HG2
Kim, TH1
Kim, HJ1
Kang, JH1
Lee, SH2
Kim, DW2
Heo, DS2
Park, I1
Ryu, MH3
Lee, SS6
Sohn, BS1
Kim, EK1
Park, DH2
Suh, DW1
Lee, SK2
Kim, MH2
Lee, J1
Morise, Z1
Sugioka, A1
Tanahashi, Y1
Kagawa, T1
Takeura, C1
Yashima, Y3
Arizumi, T2
Sasahira, N5
Hirano, K4
Tsujino, T4
Kawabe, T1
Omata, M4
Murakami, Y2
Uemura, K2
Sudo, T2
Hayashidani, Y1
Nakamura, H1
Nakashima, A2
Sueda, T2
Yoon, DH1
Lee, HJ1
Hong, YS2
Kang, YK2
Lee, JS1
Yamamoto, K3
Kawakubo, K2
Muneoka, K1
Shirai, Y1
Wakai, T1
Sakata, J1
Kanda, J1
Wakabayashi, H1
Hatakeyama, K1
Yoshimura, K1
Tsumura, T1
Asada, M1
Suzuki, C1
Niimi, M1
Nishimura, T1
Nitta, T1
Yasuchika, K1
Taura, K1
Mori, Y1
Hamada, A1
Inoue, N1
Tada, S1
Yanagihara, K1
Yazumi, S1
Osaki, Y1
Chiba, T1
Fukushima, M1
Uemoto, S1
Jang, G1
Lim, HS1
Bae, KS1
Shin, JG1
Takahara, T1
Nitta, H1
Hasegawa, Y1
Itou, N1
Takahashi, M1
Nishizuka, S1
Wakabayashi, G1
Sakabe, R1
Kobayashi, H1
Kondo, N1
Nakagawa, N1
Katayose, Y1
Ohtsuka, H1
Kitamura, Y1
Masuda, K1
Nakagawa, K1
Yoshida, H1
Onogawa, T1
Motoi, F1
Naitoh, T1
Rikiyama, T1
Egawa, S1
Unno, M1
Kang, MJ1
Ahn, S1
Seo, DW1
Andou, T1
Kameda, R1
Yamamoto, N1
Morinaga, S1
Takezako, Y1
Lee, KW1
Kim, SW1
Yoon, YB1
Yonemoto, N1
Yamao, K1
Funakoshi, A2
Tanaka, K1
Nagase, M1
Saisho, H1
Sawaki, A1
Masumoto, T1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-arm, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Carrilizumab Combinated With Gemcitabine and Oxaliplatin (GEMOX) as a Preoperative Translational Therapy for Unresectable Gallbladder Cancer[NCT05919095]Phase 237 participants (Anticipated)Interventional2023-06-30Not yet recruiting
Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma[NCT04662112]Phase 1/Phase 240 participants (Actual)Interventional2021-06-15Active, not recruiting
PD-1 Antibody Plus Gemcitabine and Oxaliplatin (GEMOX) as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma Patients With Positively Metastatic Lymph Nodes : a Single Arm, Phase II Trial[NCT05430698]Phase 262 participants (Anticipated)Interventional2023-01-31Recruiting
A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer[NCT02425137]Phase 251 participants (Actual)Interventional2015-04-30Completed
Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703]Phase 238 participants (Actual)Interventional2005-08-31Completed
Phase I/II Study of Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer[NCT01284413]Phase 1/Phase 268 participants (Actual)Interventional2010-12-31Completed
Randomized Phase III Trial Comparing Gemcitabine/Cisplatin/S-1 With Gemcitabine/Cisplatin for Unresectable Biliary Tract Cancer[NCT02182778]Phase 3246 participants (Actual)Interventional2014-07-09Completed
Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer[NCT01375972]Phase 292 participants (Actual)Interventional2008-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for oxonic acid and Biliary Tract Cancer

ArticleYear
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives.
    Current opinion in oncology, 2020, Volume: 32, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy,

2020
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
    Japanese journal of clinical oncology, 2020, Dec-16, Volume: 50, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy,

2020
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    The Cochrane database of systematic reviews, 2018, Apr-06, Volume: 4

    Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B

2018
[5 -fluoropyrimidines for treatment of biliary tract cancers].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cape

2006

Trials

33 trials available for oxonic acid and Biliary Tract Cancer

ArticleYear
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 12-01, Volume: 30, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deo

2019
Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
    Annals of surgical oncology, 2020, Volume: 27, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cho

2020
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
    Cancer medicine, 2021, Volume: 10, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neo

2021
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.
    Cancer research and treatment, 2018, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Drug Administr

2018
A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT).
    Japanese journal of clinical oncology, 2018, Apr-01, Volume: 48, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvan

2018
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
    Investigational new drugs, 2019, Volume: 37, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Drug Combinati

2019
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
    Annals of surgery, 2019, Volume: 270, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxy

2019
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycy

2013
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
    Cancer science, 2013, Volume: 104, Issue:9

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar

2013
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
    Cancer science, 2013, Volume: 104, Issue:9

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar

2013
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
    Cancer science, 2013, Volume: 104, Issue:9

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar

2013
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
    Cancer science, 2013, Volume: 104, Issue:9

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar

2013
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C

2015
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2015
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2015
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2015
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2015
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
    World journal of gastroenterology, 2014, Dec-28, Volume: 20, Issue:48

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; De

2014
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2015
Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neo

2015
Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer.
    Journal of hepato-biliary-pancreatic sciences, 2015, Volume: 22, Issue:9

    Topics: Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relati

2015
Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
    World journal of gastroenterology, 2015, May-21, Volume: 21, Issue:19

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy

2015
Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B

2016
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycyti

2016
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Anticancer research, 2017, Volume: 37, Issue:2

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co

2017
Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer.
    Chemotherapy, 2008, Volume: 54, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Disease Progression;

2008
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine;

2010
A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction.
    Investigational new drugs, 2011, Volume: 29, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Dose-Response Relationship, Drug; Drug

2011
Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

2010
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine;

2011
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract

2012
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
    British journal of cancer, 2011, Feb-15, Volume: 104, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydrox

2011
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvan

2012
Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytid

2012
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia

2012
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia

2012
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia

2012
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bilia

2012
A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2013
Phase II study of S-1 in patients with advanced biliary tract cancer.
    British journal of cancer, 2004, Nov-15, Volume: 91, Issue:10

    Topics: Administration, Oral; Adult; Aged; Biliary Tract Neoplasms; Drug Administration Schedule; Drug Combi

2004
A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2008
S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Drug Combinat

2008

Other Studies

22 other studies available for oxonic acid and Biliary Tract Cancer

ArticleYear
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
    Scientific reports, 2022, 01-19, Volume: 12, Issue:1

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; C

2022
[Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2022, Volume: 142, Issue:9

    Topics: Biliary Tract Neoplasms; Deoxycytidine; Gemcitabine; Humans; Oxonic Acid; Prognosis; Pyridines; Recu

2022
ASO Author Reflections: Phase II Trial of Adjuvant Chemotherapy with S-1 for Node-Positive Biliary Tract Cancer (N-SOG 09).
    Annals of surgical oncology, 2020, Volume: 27, Issue:7

    Topics: Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Drug Combinatio

2020
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
    Investigational new drugs, 2021, Volume: 39, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Ne

2021
The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer.
    Anticancer research, 2018, Volume: 38, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2018
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
    International journal of clinical oncology, 2018, Volume: 23, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma, Papillary; Carcino

2018
Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
    Fukuoka igaku zasshi = Hukuoka acta medica, 2013, Volume: 104, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tr

2013
A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Chemoradiotherapy; Disease-Free Survival; Drug Combi

2014
Curative Resection After Gemcitabine, Cisplatin and S-1 Chemotherapy for Initially Unresectable Biliary Duct Cancer: A Case Report.
    Anticancer research, 2015, Volume: 35, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvan

2015
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
    Cancer research and treatment, 2017, Volume: 49, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tu

2017
Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
    Investigational new drugs, 2017, Volume: 35, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2017
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    BMC cancer, 2008, Dec-18, Volume: 8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2008
Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients.
    Oncology, 2009, Volume: 76, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2009
Treatment of patients with unresectable advanced carcinoma of biliary tract - chemotherapy and surgical resection.
    Anticancer research, 2009, Volume: 29, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Combined M

2009
S-1 monotherapy in patients with advanced biliary tract cancer.
    Oncology, 2009, Volume: 77, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neopl

2009
Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
    Annals of surgery, 2009, Volume: 250, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Chemotherapy, Adjuvant; D

2009
Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary

2011
[Effect of pylorus-preserving pancreaticoduodenectomy on serum levels of 5-fluorouracil during S-1 treatment for pancreaticobiliary malignancy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:8

    Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Drug Combinations; Female; Fluoroura

2010
Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
    Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In

2012
An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:115

    Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; C

2012
A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:9

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract

2012
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisp

2007